Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Carcinoid Tumor × Octreotide × Clear all

Phase

Status

Completed 4 Withdrawn 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Gastrointestinal 1 Endocrine 1

Conditions

Neuroendocrine Tumors 2 Gastro-enteropancreatic neuroendocrine tumor 2 Pancreatitis 1 Pancreatic Intraductal Neoplasms 1 Meningioma 1 Fistula 1 Duodenal Neoplasms 1 Carcinoid Tumor 1 Adenoma, Islet Cell 1

Interventions

Everolimus 2 zimberelimab 1 olaparib 1 lutetium Lu 177 dotatate 1 lanreotide 1 cabozantinib 1 Sunitinib 1 Octreotide 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05477576 2026-01-20

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡